Publications:  Prof Peter Szlosarek

Wong PP, Muñoz-Félix JM, Hijazi M, Kim H, Robinson SD, De Luxán-Delgado B, Rodríguez-Hernández I, Maiques O et al.(2020). Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells. Cell vol. 181, (6) 1346-1363.e21.

Tsao M-S, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry M-C et al.(2019). Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. J Thorac Oncol vol. 14, (10) 1704-1717.

Szlosarek P (2019). Pegargiminase to Treat Mesothelioma. JOURNAL OF THORACIC ONCOLOGY. vol. 14, S19-S20.

Kawsar A, Patel P, Markiewicz D, Szlosarek P, Phillips M, Harwood C (2019). Histological features of cutaneous toxicity with checkpoint-inhibitor immunotherapy for metastatic melanoma: a retrospective case series. BRITISH JOURNAL OF DERMATOLOGY. vol. 181, 117-117.

Wimalasingham AG, Phillips MM, Lim L, Rashid S, Hall PE, Khadeir R, Steele JPC, Conibear J et al. (2019). Phase 1 dose-expansion study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1 (ASS1)-deficient non-squamous non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 37,

Hall PE, Lewis R, Syed N, Shaffer R, Evanson J, Ellis S, Williams M, Feng X et al.(2019). A phase I study of pegylated arginine deiminase (Pegargiminase), cisplatin, and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma. Clinical Cancer Research vol. 25, (9) 2708-2716.

Atkinson A, Renziehausen A, Wang H, Lo Nigro C, Lattanzio L, Merlano M, Rao B, Weir L et al.(2019). Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma. Journal of Investigative Dermatology vol. 139, (5) 1118-1126.

Turner EC, Szlosarek PW, Vousden KH (2019). Argininosuccinate Synthetase (ASS1) Expression in Pancreatic Ductal Adenocarcinoma and Response to Arginine Deprivation. JOURNAL OF PATHOLOGY. vol. 248, S21-S21.

Renziehausen A, Wang H, Rao B, Weir L, Nigro CL, Lattanzio L, Merlano M, Vega-Rioja A et al. (2019). The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention. Oncogene. vol. 38, 2320-2336.

Przystal JM, Hajji N, Khozoie C, Renziehausen A, Zeng Q, Abaitua F, Hajitou A, Suwan K et al.(2018). Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM. Cell Death Dis vol. 9, (12)

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM et al.(2018). Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. Journal of Thoracic Oncology vol. 13, (11) 1655-1667.

Hall P, Lewis R, Syed N, Shaffer R, Evanson J, Ellis S, Williams M, Feng X et al. (2018). A PHASE I EXPANSION STUDY OF PEGARGIMINASE, CISPLATIN AND PEMETREXED IN ARGININOSUCCINATE SYNTHETASE 1-NEGATIVE RECURRENT HIGH GRADE GLIOMAS (HGGS). NEURO-ONCOLOGY. vol. 20, 345-345.

Keshet R, Szlosarek P, Carracedo A, Erez A(2018). Rewiring urea cycle metabolism in cancer to support anabolism. Nat Rev Cancer vol. 18, (10) 634-645.

Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T et al.(2018). Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. European Journal of Cancer vol. 102, 49-51.

Fennell DA, Kirkpatrick EV, Cozens K, Danson S, Hanna GG, Lester JF, Lord J, Nye M et al. (2018). CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. JOURNAL OF CLINICAL ONCOLOGY. vol. 36,

Chan PY, Phillips MM, Khadeir R, Ellis S, Thomson J, Johnston A, Feng X, Wu B-W et al. (2018). Phase 1 study of pegargiminase combined with cisplatin and pemetrexed in patients with ASS1-deficient uveal melanoma. JOURNAL OF CLINICAL ONCOLOGY. vol. 36,

Zauderer MG, Szlosarek P, Le Moulec S, Popat S, Taylor P, Planchard D (2018). Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation. JOURNAL OF CLINICAL ONCOLOGY. vol. 36,

Fennell DA, Kirkpatrick E, Cozens K, Nye M, Lester J, Hanna G, Steele N, Szlosarek P et al.(2018). CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials vol. 19, (1)

Cohen VML, Pavlidou E, DaCosta J, Arora AK, Szyszko T, Sagoo MS, Szlosarek P(2018). Staging Uveal Melanoma with Whole-Body Positron-Emission Tomography/Computed Tomography and Abdominal Ultrasound: Low Incidence of Metastatic Disease, High Incidence of Second Primary Cancers. Middle East Afr J Ophthalmol vol. 25, (2) 91-95.

Hanna G, Griffiths G, Kirkpatrick EV, Cozens K, Kalevras M, Maishman T, Danson S, Lester J et al. (2018). CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. LUNG CANCER. vol. 115, S84-S84.

Khadeir R, Szyszko T, Szlosarek PW(2017). Optimizing arginine deprivation for hard-to-treat cancers. Oncotarget vol. 8, (57) 96468-96469.

Adams E, Cheng C-Y, Sacco J, Danson S, Corrie P, Nathan P, Szlosarek P, Upton J et al. (2017). Mapping the treatment pathway for metastatic uveal melanoma (mUM) patients in England: A qualitative pilot study. JOURNAL FOR IMMUNOTHERAPY OF CANCER. vol. 5,

Fennell D, Kirkpatrick E, Cozens K, Danson S, Hanna G, Lester J, Lord J, Nye M et al. (2017). CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma. JOURNAL OF THORACIC ONCOLOGY. vol. 12, S2376-S2376.

Chan PY, Hall P, Hay G, Cohen VML, Szlosarek PW(2017). A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity. Pigment Cell Melanoma Res vol. 30, (6) 558-562.

Beddowes E, Spicer J, Chan PY, Khadeir R, Garcia Corbacho J, Repana D, Steele JP, Schmid P et al.(2017). Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1–deficient thoracic cancers. Journal of Clinical Oncology vol. 35, (16) 1778-1785.

Szlosarek PW, Baas P, Ceresoli GL, Fennell DA, Gilligan D, Johnston A, Lee P, Mansfield AS et al. (2017). ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG2O or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma. JOURNAL OF CLINICAL ONCOLOGY. vol. 35,

Phillips M, Szyszko T, Hall P, Cook GJR, Khadeir R, Steele JPC, Spicer JF, Feng X et al. (2017). Expansion study of ADI-PEG 20, pemetrexed and cisplatin in patients with ASS1-deficient malignant pleural mesothelioma (TRAP). JOURNAL OF CLINICAL ONCOLOGY. vol. 35,

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al.(2017). Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. JAMA oncology vol. 3, (1) 58-66.

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al.(2017). Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma a randomized clinical trial. JAMA Oncology vol. 3, (1) E1-E9.

Szyszko TA, Bomalaski JS, Goh V, Barrington SF, Cook GJR, Szlosarek PW (2016). TRAP substudy: assessment of 18-FLT PET/CT to examine tumour proliferation in patients with ASS1-deficient thoracic cancers treated with arginine deiminase (ADI)-PEG20, pemetrexed and cisplatin. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. vol. 43, S354-S354.

Locke M, Ghazaly E, Freitas MO, Mitsinga M, Lattanzio L, Lo Nigro C, Nagano A, Wang J et al.(2016). Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1. Cell Reports vol. 16, (6) 1604-1613.

Szlosarek PW, Locke M, Ghazaly E, Lattanzio L, Lo Nigro C, Martin SA (2016). Inhibition of the polyamine synthesis pathway is synthetically lethal with loss of argininosuccinate synthase 1 in cancer. vol. 76,

Szlosarek PW, Szyszko T, Pacey S, Spicer JF, Phillips M, Steele JPC, Barba A, Diaz M et al. (2016). 18-FLT-PET/CT as an imaging biomarker in patients with ASS1-deficient thoracic cancers treated with ADI-PEG20, pemetrexed and cisplatin. JOURNAL OF CLINICAL ONCOLOGY. vol. 34,

Karydis I, Chan PY, Wheater M, Arriola E, Szlosarek PW, Ottensmeier CH(2016). Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology vol. 5, (5)

Burrows N, Cane G, Robson M, Gaude E, Howat WJ, Szlosarek PW, Pedley RB, Frezza C et al.(2016). Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20). Sci Rep vol. 6,

Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Arozena AA, Adachi H, Adams CM et al.(2016). Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy vol. 12, (1) 1-222.

Szyszko TA, Yip C, Szlosarek P, Goh V, Cook GJ(2016). The role of new PET tracers for lung cancer. Lung cancer (Amsterdam, Netherlands) vol. 94, 7-14.

Nathan P, Cohen V, Coupland S, Curtis K, Damato B, Evans J, Fenwick S, Kirkpatrick L et al.(2015). Uveal Melanoma UK National Guidelines. European Journal of Cancer vol. 51, (16) 2404-2412.

Phillips MM, Khadeir R, Tookman L, McCarthy F, Steele J, Bomalaski J, Ghazaly E, Szlosarek PW (2015). Macrophages promote resistance to pegylated arginine deiminase in malignant pleural mesothelioma. CANCER RESEARCH. vol. 75,

Pazmandi J, O'Neill KS, Scheck AC, Szlosarek PW, Woolf EC, Brooks KS, Syed N (2015). The ketogenic diet alters the expression of microRNAs that play key roles in tumor development. CANCER RESEARCH. vol. 75,

Khadeir RS, Phillips MM, Sgoo MS, Arora A, Cohen V, Thaung C, Szlosarek PW (2015). Widespread deficiency of ASS1 in uveal melanoma and sensitivity to pegylated arginine deiminase. CANCER RESEARCH. vol. 75,

Gale J, Van-de-Velde V, Szlosarek P, Langhurst H, Harwood C (2015). Two diverse skin complications of common variable immunodeficiency. BRITISH JOURNAL OF DERMATOLOGY. vol. 173, 139-140.

Miraki-Moud F, Ghazaly E, Ariza-McNaughton L, Hodby KA, Clear A, Anjos-Afonso F, Liapis K, Grantham M et al.(2015). Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. Blood vol. 125, (26) 4060-4068.

Szlosarek PW, Spicer JF, Szyszko T, Cook GJR, Chan PY, Hategan M, Repana D, Steele JP et al. (2015). Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,

Cutts R, Jithesh PV, Delage B, Luong P, Thomas G, Chelala C, Szlosarek PW (2014). Gene expression analysis of argininosuccinate synthetase loss and the effects of pegylated arginine deiminase in malignant pleural mesothelioma. CANCER RESEARCH. vol. 74,

Szlosarek PW(2014). Arginine deprivation and autophagic cell death in cancer. Proc Natl Acad Sci U S A vol. 111, (39) 14015-14016.

Ghazaly EA, Luong P, Chmielewska-Kassassir M, Wozniak L, Bomalaski JS, Gribben JG, Szlosarek PW (2014). Metabolomic analysis of pegylated arginine deiminase treatment in patients with malignant pleural mesothelioma. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer JF, Lind MJ, Bomalaski JS et al. (2014). Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,

Pavlidou E, Arora A, Somerville E, Sagoo MS, Szlosarek P, Cohen V (2014). The value of whole body (18) fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and abdominal ultrasound in staging of patients with uveal melanoma. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. vol. 55,

Rintoul RC, Rassl DM, Maskell N, Gittins J, Szlosarek PW, Kerr KM, Booton R, Hughes V et al.(2014). MesobanK - a UK based bioresource for malignant mesothelioma. LUNG CANCER vol. 83, S82-S82.

Szlosarek PW, Lee SJ, Pollard PJ(2014). Rewiring mitochondrial pyruvate metabolism: Switching off the light in cancer cells?. Molecular Cell vol. 56, (3) 343-344.

Phillips MM, Sheaff MT, Szlosarek PW(2013). Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat vol. 45, (4) 251-262.

Allen MD, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M et al.(2013). Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Research vol. 74, (3) 896-907.

Miraki-Moud F, Ariza-McNaughton L, Ghazaly EA, Hodby KA, Luong P, Clear A, Sohrabi F, Bomalaski J et al. (2013). Arginine Deprivation With Pegylated Arginine Deiminase Induces Death Of Acute Myeloid Leukaemia Cells In Vivo. BLOOD. vol. 122,

Szlosarek PW, Steele J, Sheaff M, Szyszko T, Ellis S, Nolan L, Taylor P, Gilligan D et al.(2013). A RANDOMISED PHASE II TRIAL OF PEGYLATED ARGININE DEIMINASE IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA. JOURNAL OF THORACIC ONCOLOGY vol. 8, S308-S308.

Rintoul RC, Rassl DM, Maskell NA, Szlosarek PW, Kerr KM, Booton R, Hughes V, Fennell D et al. (2013). MESOBANK: A UK BASED BIORESOURCE FOR MALIGNANT PLEURAL MESOTHELIOMA. JOURNAL OF THORACIC ONCOLOGY. vol. 8, S940-S940.

Sommerlad M, Purdie K, Rizvi H, McGregor JM, Szlosarek P, Wolstenholme V, Cerio R, Harwood C (2013). Vemurafenib, photosensitivity and human papillomavirus infection: an emerging story. BRITISH JOURNAL OF DERMATOLOGY. vol. 169, 9-9.

Zheng L, MacKenzie ED, Karim SA, Hedley A, Blyth K, Kalna G, Watson DG, Szlosarek P et al.(2013). Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells. Cancer Metab vol. 1, (1)

Szlosarek PW, Luong P, Phillips MM, Baccarini M, Stephen E, Szyszko T, Sheaff MT, Avril N(2013). Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol vol. 31, (7) e111-e113.

Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E et al.(2013). Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis vol. 4,

Matin RN, Szlosarek P, McGregor JM, Cerio R, Harwood CA(2013). Synchronous melanoma and renal carcinoma: a clinicopathological study of five cases. Clin Exp Dermatol vol. 38, (1) 47-49.

Lewis A, Hough N, Woolf DK, Trehy R, Kolotia B, Reeves A, Szlosarek PW, Wells P et al.(2013). Systemic therapy in the management of non small cell lung cancer (NSCLC): The real world experience. LUNG CANCER vol. 79, S17-S17.

Hough N, Lewis A, Woolf DK, Trehy R, Kolotia B, Reeves A, Szlosarek PW, Wells P et al.(2013). Three years experience of chemotherapy for small cell lung cancer at a tertiary referral centre. LUNG CANCER vol. 79, S65-S65.

Coward JIG, Ding N-L, Feakins R, Kocher H, Popat S, Szlosarek PW(2012). Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report. Med Oncol vol. 29, (4) 2623-2625.

Syed N, Roncaroli F, Janczar K, Singh P, O'Neil K, Lo Nigro C, Lattanzio L, Coley HM et al. (2012). TRANSCRIPTIONAL SILENCING DISRUPTS TWO LEVELS OF ARGININE BIOSYNTHESIS IN GLIOBLASTOMA MULTIFORME (GBM): A NOVEL, TARGETED THERAPEUTIC STRATEGY FOR GBM. NEURO-ONCOLOGY. vol. 14, 11-11.

Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A et al.(2012). Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis vol. 3,

Hatzimichael E, Dasoula A, Syed N, Szlosarek PW, Dranitsaris G, Crook T, Briasoulis EC (2012). Epigenetic inactivation to target the arginine biosynthetic pathway in multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. vol. 30,

Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K et al.(2012). NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer vol. 106, (8) 1446-1452.

Matin RN, Gonzalez D, Thompson L, Lambert SR, Bakr F, Dhomen N, Marais R, McGregor JM et al.(2012). KIT and BRAF mutational status in a patient with a synchronous lentigo maligna melanoma and a gastrointestinal stromal tumor. Am J Clin Dermatol vol. 13, (1) 64-65.

Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, Blagden SP et al.(2011). Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res vol. 71, (9) 3317-3327.

Allen M, Syed N, Luong F, Howarth K, Gorman P, Tomlinson I, Roylance R, Lu Y-J et al.(2011). Epigenetic silencing of argininosuccinate synthetase renders human bladder cancer cells sensitive to pegylated arginine deiminase. CANCER RESEARCH vol. 71,

Szlosarek PW, Luong F, Clear A, Taussig D, Joel S, Calaminici M, Debernardi S, Fitzgibbon J et al.(2011). Pegylated arginine deiminase (ADI-PEG20) as a potential novel therapy for argininosuccinate synthetase-deficient acute myeloid leukemia. CANCER RESEARCH vol. 71,

Syed N, O'Neilli K, Hughes M, LoNigro C, Lattanzio L, Szlosarek P, Roncaroli F, Crook T(2011). Transcriptional silencing disrupts two levels of arginine biosynthesis in glioblastoma multiforme: a novel, targeted therapeutic strategy for high grade gliomas. CANCER RESEARCH vol. 71,

Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW(2010). Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer vol. 126, (12) 2762-2772.

Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A et al.(2009). Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer vol. 125, (6) 1454-1463.

Matin RN, Harwood CA, McAndrew L, Cerio R, Szlosarek P (2009). A clinicopathological study of cases of synchronous melanoma and renal carcinoma. BRITISH JOURNAL OF DERMATOLOGY. vol. 161, 19-19.

Lim SL, Smith P, Syed N, Coens C, Wong H, van der Burg M, Szlosarek P, Crook T et al.(2008). Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. BRIT J CANCER vol. 98, (8) 1452-1456.

Szlosarek PW, Grimshaw MJ, Wilbanks GD, Hagemann T, Wilson JL, Burke F, Stamp G, Balkwill FR(2007). Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer. Int J Cancer vol. 121, (1) 6-11.

Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP et al.(2006). In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res vol. 12, (23) 7126-7131.

Szlosarek PW, Fennell DA, Rudd RM, Lind M, Ranson M, Hackshaw A, Bomalaski JS, Steele JPC(2006). A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma. LUNG CANCER vol. 54, S54-S54.

Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Balkwill FR, Fennell D (2006). Arginine depletion upregulates Bax and triggers apoptosis of malignant mesothelioma cells deficient in argininosuccinate synthetase. CANCER RESEARCH. vol. 66,

Szlosarek P, Charles KA, Balkwill FR(2006). Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer vol. 42, (6) 745-750.

Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, Balkwill FR(2006). Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther vol. 5, (2) 382-390.

Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL(2005). The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res vol. 65, (22) 10355-10362.

Szlosarek PW, Grimshaw MJ, Wilbanks GD, Burke F, Wilson JL, Balkwill FR (2004). Regulation and expression of argininosuccinate synthetase in human ovarian cancer. BRITISH JOURNAL OF CANCER. vol. 91, S57-S57.

Szlosarek P, Balkwill F(2004). The inflammatory cytokine network of epithelial cancer: therapeutic implications. Novartis Found Symp vol. 256, 227-237.

Szlosarek PW, Balkwill FR(2003). Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol vol. 4, (9) 565-573.

Nicholson S, Guile K, John J, Clarke IA, Diffley J, Donnellan P, Michael A, Szlosarek P et al.(2003). A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma. MELANOMA RES vol. 13, (4) 389-393.

Szlosarek PW(2001). Recent advances in palliative care - United Kingdom continues to lead in palliative care. BRIT MED J vol. 322, (7280) 234-234.